Cyprotex (LSE:CRX) Scaled Net Operating Assets : 0.53 (As of Jun. 2016)

View and export this data going back to 2002. Start your Free Trial

What is Cyprotex Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Cyprotex's operating assets for the quarter that ended in Jun. 2016 was £9.67 Mil. Cyprotex's operating liabilities for the quarter that ended in Jun. 2016 was £1.52 Mil. Cyprotex's Total Assets for the quarter that ended in Dec. 2015 was £15.47 Mil. Therefore, Cyprotex's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2016 was 0.53.

Cyprotex Scaled Net Operating Assets Historical Data

The historical data trend for Cyprotex's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyprotex Scaled Net Operating Assets Chart

Cyprotex Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.80

0.73

0.42

0.64

Cyprotex Semi-Annual Data
	Dec06	Jun07	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.12	0.43	0.61	0.62	0.53

Competitive Comparison of Cyprotex's Scaled Net Operating Assets

For the Biotechnology subindustry, Cyprotex's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyprotex's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyprotex's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Cyprotex's Scaled Net Operating Assets falls into.

Cyprotex Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Cyprotex's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2015 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2015 )
=	(Operating Assets (A: Dec. 2015 )	-	Operating Liabilities (A: Dec. 2015 ))	/	Total Assets (A: Dec. 2014 )
=	(10.056	-	1.752)	/	13.044
=	0.64

where

	Operating Assets		(A: Dec. 2015 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	15.466	-	5.41
=	10.056

	Operating Liabilities		(A: Dec. 2015 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	19.241	-	17.279	-	0.21
=	1.752

Cyprotex's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2016 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Jun. 2016 )
=	(Operating Assets (Q: Jun. 2016 )	-	Operating Liabilities (Q: Jun. 2016 ))	/	Total Assets (Q: Dec. 2015 )
=	(9.674	-	1.524)	/	15.466
=	0.53

where

	Operating Assets		(Q: Jun. 2016 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	16.492	-	6.818
=	9.674

	Operating Liabilities		(Q: Jun. 2016 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	17.163	-	15.436	-	0.203
=	1.524

Cyprotex Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Cyprotex's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyprotex (LSE:CRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyprotex PLC (LSE:CRX) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cyprotex.com

Cyprotex PLC was incorporated on October 25, 2001. The Company together with its subsidiaries, provides in vitro and in silico ADMET and PK (absorption, distribution, metabolism, excretion, toxicity and pharmacokinetics) information to a number of different industries including the Pharmaceutical, Biotechnology, Cosmetic, Personal Care, Agrochemical, Chemical Industries and Academia. It provides a range of ADME Tox contract research services, which includes ADME screening, Customized ADME assays, Genomic ADME, In silico pharmacokinetics modeling and In vitro toxicology. It also offers integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical. The Company operates in North America, Mainland Europe and United Kingdom.

Cyprotex (LSE:CRX) Headlines

No Headlines